Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors.
2015 ◽
Vol 33
(15_suppl)
◽
pp. 2522-2522
◽
2017 ◽
Vol 35
(6)
◽
pp. 782-790
◽
2011 ◽
Vol 34
(8)
◽
pp. 1223-1226
◽
2018 ◽
Vol Volume 12
◽
pp. 495-504
◽
2013 ◽
Vol 32
(2)
◽
pp. 303-311
◽
2006 ◽
Vol 4
(12)
◽
pp. 195
◽
2008 ◽
Vol 6
(12)
◽
pp. 127-128
2014 ◽
Vol 30
(10)
◽
pp. 847-853
◽